Author

María‐Jesús Vidal

Observed names: M.J. Roncero Vidal, M.J. Vidal, María-Jesús Vidal

Institution: Hospital Universitario de León

Observed institutions: Institut Català d'Oncologia, Donostiako Unibertsitate Ospitalea, Duran i Reynals Hospital, Hospital Universitario de León

OpenAlex ID: A5078766249

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

2005 · A. Sureda, M. Constans, et al. · Annals of Oncology · 220

Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

2020 · Claudia Pérez‐Carretero, María Hernández‐Sánchez, et al. · International Journal of Cancer · 35

Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials

2021 · Josep‐Maria Ribera, Josep‐Maria Ribera, et al. · Hematological Oncology · 12

TRAF3 alterations are frequent in del‐3′ IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features

2022 · Claudia Pérez‐Carretero, María Hernández‐Sánchez, et al. · American Journal of Hematology · 10

Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)

2017 · A. García-Noblejas, J. Cannata-Ortiz, et al. · Annals of Hematology · 6

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

2016 · Eva González-Barca, Miguel A. Canales, et al. · Acta Haematologica · 6

From Clinical Perception to Implicit Bias: Understanding Personality Traits in Lymphoma Patients

2025 · Fátima Roso-Bas, María Dolores Alonso-Llobregat, et al. · Cancers · 1

Author response for "Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials"

2021 · Josep‐Maria Ribera, Mireia Morgades, et al.

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

2020 · Pau Abrisqueta Costa, Javier Loscertales, et al. · Blood

S869 Tipifarnib in Relapsed or Refractory Angioimmunoblastic T‐cell Lymphoma (aitl) and Cxcl12+ Peripheral T‐cell Lymphoma (ptcl): Preliminary Results From an Open‐label, Phase 2 Study

2019 · T. Witzig, L. Sokol, et al. · HemaSphere

Chronic Lymphocytic Leukemia Patients with IGH Rearrangements Are Characterized By a Distinct Genetic Landscape with Prognostic Implications

2018 · Claudia Pérez Carretero, Maria Hernandez-Sanchez, et al. · Blood

Works count: 11

Citation count: 290

H-index: 6

I10-index: 4